CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Efficacy and safety of etrasimod in patients with moderate to severe isolated proctitis compared with patients with more extensive disease: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
DOI 10.1055/s-0043-1771741
Bibliografische Angaben
Nachweis in CareLit
Autor:innenL. Peyrin-Biroulet, M. C. Dubinsky, B. E. Sands, J. Panés, S. Schreiber, W. Reinisch, B. G. Feagan, S. Danese, A. Yarur, G. D’Haens, M. Goetsch, K. Wosik, J. Wu, I. Modesto, A. McDonnell, L. Bartolome, C. J. Rabbat, S. Vermeire
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2023
Jahrgang / SeitenJg. 61 · S. e416-e417
Kernaussage aus der Literatur
Abstract-Vorschau
Efficacy and safety of etrasimod in patients with moderate to severe isolated proctitis compared with patients with more extensive disease: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Zitieren
Zitierempfehlung
L. Peyrin-Biroulet, M. C. Dubinsky, B. E. Sands, J. Panés, S. Schreiber, W. Reinisch, B. G. Feagan, S. Danese, A. Yarur, G. D’Haens, M. Goetsch, K. Wosik, J. Wu, I. Modesto, A. McDonnell, L. Bartolome, C. J. Rabbat, S. Vermeire (2023) Efficacy and safety of etrasimod in patients with moderate to severe isolated proctitis compared with patients with more extensive disease: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials. Zeitschrift für Gastroenterologie, 61 (08), e416-e417. https://doi.org/10.1055/s-0043-1771741
Mit CareLit weiterarbeiten